Phase Ib/II Trial of Nal-Irinotecan and Nivolumab as Second-Line Treatment in Patients With Advanced Biliary Tract Cancer
University of Michigan Rogel Cancer Center
University of Michigan Rogel Cancer Center
Hoffmann-La Roche
Hoffmann-La Roche
Bristol-Myers Squibb
Mayo Clinic
NuCana plc
Case Comprehensive Cancer Center
Ludwig Institute for Cancer Research
SWOG Cancer Research Network
Sumitomo Pharma America, Inc.
MedImmune LLC
Cantargia AB
Incyte Corporation
National Cancer Institute (NCI)
University of Louisville
Isofol Medical AB
Abramson Cancer Center at Penn Medicine
SCRI Development Innovations, LLC
AstraZeneca
University College, London
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University Hospital Tuebingen
The University of Texas Health Science Center at San Antonio
CTI BioPharma
Mayo Clinic
Hokkaido Gastrointestinal Cancer Study Group